| 1 | Barriers and facilitators to implementation of intravenous cardiovascular treatments in ambulatory settings | 2.0 | 3 | Citations (PDF) |
| 2 | Large-bore Mechanical Thrombectomy Versus Catheter-directed Thrombolysis in the Management of Intermediate-risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial | 13.9 | 202 | Citations (PDF) |
| 3 | Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS) | 1.9 | 20 | Citations (PDF) |
| 4 | The Cochrane Library | 3.3 | 2 | Citations (PDF) |
| 5 | Water Hammer Phenomenon in Coronary Arteries: Scientific Basis for Diagnostic and Predictive Modeling with Acoustic Action Mapping | 2.3 | 4 | Citations (PDF) |
| 6 | Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful? | 0.5 | 6 | Citations (PDF) |
| 7 | Cost-Effectiveness of the CADScor System in Low-Risk Patients Presenting to the Emergency Department with Chest Pain | 1.5 | 2 | Citations (PDF) |
| 8 | Ocular safety of glucagon-like peptide-1 receptor agonists: insights and unanswered questions. Authors' reply. | 0.5 | 1 | Citations (PDF) |
| 9 | Visual art and representation in cardiology: Past, present, and future | 1.9 | 2 | Citations (PDF) |
| 10 | Cardiovascular Research Technologies 2025: Beyond the Guidelines: DAPT selection and duration before and after PCI | 0.5 | 0 | Citations (PDF) |
| 11 | Worldwide impact of COVID-19 on hospital admissions for non-ST-elevation acute coronary syndromes (NSTACS): a systematic review with meta-analysis of 553 038 cases. | 2.5 | 10 | Citations (PDF) |
| 12 | The Cochrane Library | 3.3 | 6 | Citations (PDF) |
| 13 | Top bar navigation | 1.7 | 12 | Citations (PDF) |
| 14 | Thrombin as target for prevention of recurrent events after acute coronary syndromes | 1.6 | 10 | Citations (PDF) |
| 15 | Posttraumatic Stress Disorder After Spontaneous Coronary Artery Dissection: A Report of the International Spontaneous Coronary Artery Dissection Registry | 3.2 | 25 | Citations (PDF) |
| 16 | Flowing Beyond Conventions | 2.0 | 2 | Citations (PDF) |
| 17 | Trends in Percutaneous Device Use for the Treatment of Venous Thromboembolism Over Time in the PINC AI Healthcare Database and the National Inpatient Sample | 1.5 | 8 | Citations (PDF) |
| 18 | A cross-sectional study of outcomes for patients undergoing mechanical thrombectomy for pulmonary embolism during 2018–2022: Insights from the PINC AI Healthcare Database | 1.4 | 5 | Citations (PDF) |
| 19 | CSL112 (Apolipoprotein A‐I [Human]) Reduces the Elevation in Neutrophil‐to‐Lymphocyte Ratio Induced by Acute Myocardial Infarction | 3.2 | 8 | Citations (PDF) |
| 20 | IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial | 27.2 | 90 | Citations (PDF) |
| 21 | Reducing Inferiority in the Design, Conduct, Analysis, Reporting, and Interpretation of Noninferiority Trials | 1.6 | 0 | Citations (PDF) |
| 22 | Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome | 13.9 | 45 | Citations (PDF) |
| 23 | Outcomes From Mechanical Thrombectomy for Deep Vein Thrombosis: Insights From the PINC AI Healthcare Database | 1.2 | 1 | Citations (PDF) |
| 24 | Factor XIa inhibition as a therapeutic strategy for atherothrombosis | 1.2 | 9 | Citations (PDF) |
| 25 | Digital tools in heart failure: addressing unmet needs | 11.0 | 32 | Citations (PDF) |
| 26 | Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial | 7.4 | 28 | Citations (PDF) |
| 27 | Current and Future Roles of Glycoprotein IIb–IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction | 2.6 | 15 | Citations (PDF) |
| 28 | Preliminary Results in the Investigation of In Vivo Iliac and Coronary Flow Collision, Vortex Formation, and Disorganized Flow Degeneration: Insights from Invasive Cardiology Based on Fluid Mechanics Principles and Practices | 1.2 | 2 | Citations (PDF) |
| 29 | How to make cardiology clinical trials more inclusive | 27.2 | 35 | Citations (PDF) |
| 30 | Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications | 2.0 | 16 | Citations (PDF) |
| 31 | Clinical Pharmacokinetics and Pharmacodynamics of CSL112 | 2.2 | 15 | Citations (PDF) |
| 32 | The Single-Syringe Versus the Double-Syringe Techniques of Adenosine Administration for Supraventricular Tachycardia: A Systematic Review and Meta-Analysis | 2.0 | 6 | Citations (PDF) |
| 33 | MINOCA: Myocardial infarction no obstructive coronary artery disease | 1.0 | 22 | Citations (PDF) |
| 34 | Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation | 1.2 | 7 | Citations (PDF) |
| 35 | Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials | 2.7 | 56 | Citations (PDF) |
| 36 | Worldwide differences of hospitalization for ST-segment elevation myocardial infarction during COVID-19: A systematic review and meta-analysis | 1.7 | 48 | Citations (PDF) |
| 37 | Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study | 13.9 | 29 | Citations (PDF) |
| 38 | Evolution of single-lead ECG for STEMI detection using a deep learning approach | 1.7 | 35 | Citations (PDF) |
| 39 | Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX | 3.5 | 8 | Citations (PDF) |
| 40 | Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. | 2.0 | 11 | Citations (PDF) |
| 41 | Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design | 1.5 | 23 | Citations (PDF) |
| 42 | Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial | 1.6 | 4 | Citations (PDF) |
| 43 | Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial | 1.9 | 16 | Citations (PDF) |
| 44 | Independence of clinical events committees: A consensus statement from clinical research organizations | 1.9 | 6 | Citations (PDF) |
| 45 | Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity | 3.2 | 31 | Citations (PDF) |
| 46 | ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future | 3.6 | 28 | Citations (PDF) |
| 47 | Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction | 6.5 | 50 | Citations (PDF) |
| 48 | D-24 | Reducing Use of Triple Therapy after Percutaneous Coronary Intervention: Results from a Hospital-wide Quality Improvement Initiative | 1.2 | 0 | Citations (PDF) |
| 49 | P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention | 27.3 | 65 | Citations (PDF) |
| 50 | Pressure-Controlled Intermittent Coronary Sinus Occlusion: A Novel Approach to Improve Microvascular Flow and Reduce Infarct Size in STEMI | 0.5 | 11 | Citations (PDF) |
| 51 | Reducing use of triple therapy after percutaneous coronary intervention: Results from a hospital-wide quality improvement initiative | 1.3 | 2 | Citations (PDF) |
| 52 | External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial | 1.2 | 7 | Citations (PDF) |
| 53 | Reduction in Revascularization With Icosapent Ethyl | 13.9 | 54 | Citations (PDF) |
| 54 | Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction | 1.9 | 82 | Citations (PDF) |
| 55 | Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials | 2.7 | 38 | Citations (PDF) |
| 56 | Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial | 20.0 | 309 | Citations (PDF) |
| 57 | Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI | 2.0 | 38 | Citations (PDF) |
| 58 | Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials | 13.9 | 31 | Citations (PDF) |
| 59 | Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update | 13.9 | 223 | Citations (PDF) |
| 60 | Prognosis of Claims‐ Versus Trial‐Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting | 3.2 | 2 | Citations (PDF) |
| 61 | Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead | 2.4 | 19 | Citations (PDF) |
| 62 | Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults | 1.6 | 71 | Citations (PDF) |
| 63 | Comparing Baseline Data From Registries With Trials: Evidence From the CathPCI Registry and DAPT Study. | 2.0 | 3 | Citations (PDF) |
| 64 | Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective | 2.0 | 10 | Citations (PDF) |
| 65 | Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. | 2.0 | 19 | Citations (PDF) |
| 66 | Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials | 2.0 | 14 | Citations (PDF) |
| 67 | Bleeding avoidance strategies in percutaneous coronary intervention | 27.3 | 144 | Citations (PDF) |
| 68 | Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. | 7.4 | 37 | Citations (PDF) |
| 69 | Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial | 9.6 | 52 | Citations (PDF) |
| 70 | Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations | 13.9 | 282 | Citations (PDF) |
| 71 | Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT | 6.5 | 35 | Citations (PDF) |
| 72 | Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG | 13.9 | 55 | Citations (PDF) |
| 73 | The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? | 2.7 | 1 | Citations (PDF) |
| 74 | 307: COVID-19 Infodemics: How Social Media Shared Information Rapidly to Global Healthcare Teams | 0.6 | 0 | Citations (PDF) |
| 75 | Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials | 7.4 | 147 | Citations (PDF) |
| 76 | Spontaneous coronary artery dissection and its association with takotsubo syndrome: Novel insights from a tertiary center registry | 1.3 | 44 | Citations (PDF) |
| 77 | A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention | 1.3 | 13 | Citations (PDF) |
| 78 | REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States | 13.9 | 126 | Citations (PDF) |
| 79 | Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study | 1.3 | 6 | Citations (PDF) |
| 80 | <p>The AngelMed Guardian® System in the Detection of Coronary Artery Occlusion: Current Perspectives</p> | 1.4 | 5 | Citations (PDF) |
| 81 | Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial) | 1.5 | 10 | Citations (PDF) |
| 82 | Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49) | 1.5 | 31 | Citations (PDF) |
| 83 | Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS | 7.4 | 164 | Citations (PDF) |
| 84 | Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial | 1.9 | 12 | Citations (PDF) |
| 85 | Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study | 13.9 | 11 | Citations (PDF) |
| 86 | Safety and Efficacy of Double Antithrombotic Therapy With Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis | 3.2 | 70 | Citations (PDF) |
| 87 | Randomized Trials Versus Common Sense and Clinical Observation | 6.5 | 65 | Citations (PDF) |
| 88 | First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction | 3.2 | 43 | Citations (PDF) |
| 89 | Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. | 6.5 | 52 | Citations (PDF) |
| 90 | Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review | 3.2 | 56 | Citations (PDF) |
| 91 | VE-1902—A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis | 1.6 | 11 | Citations (PDF) |
| 92 | Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure | 2.0 | 26 | Citations (PDF) |
| 93 | Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. | 1.9 | 112 | Citations (PDF) |
| 94 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research | 2.4 | 218 | Citations (PDF) |
| 95 | Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective | 2.4 | 17 | Citations (PDF) |
| 96 | Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry | 3.5 | 54 | Citations (PDF) |
| 97 | Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis | 1.6 | 8 | Citations (PDF) |
| 98 | Machine learning to predict venous thrombosis in acutely ill medical patients | 0.4 | 50 | Citations (PDF) |
| 99 | Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation | 1.2 | 5 | Citations (PDF) |
| 100 | Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy | 6.5 | 77 | Citations (PDF) |
| 101 | Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease | 27.3 | 112 | Citations (PDF) |
| 102 | Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention | 6.5 | 69 | Citations (PDF) |
| 103 | Ticagrelor With or Without Aspirin After Complex PCI | 6.5 | 150 | Citations (PDF) |
| 104 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up | 6.5 | 2,285 | Citations (PDF) |
| 105 | Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials | 2.1 | 27 | Citations (PDF) |
| 106 | Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention | 3.5 | 12 | Citations (PDF) |
| 107 | Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more | 2.9 | 5 | Citations (PDF) |
| 108 | Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry | 2.4 | 1 | Citations (PDF) |
| 109 | The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX | 1.5 | 5 | Citations (PDF) |
| 110 | Implanted Monitor Alerting to Reduce Treatment Delay in Patients With Acute Coronary Syndrome Events | 6.5 | 13 | Citations (PDF) |
| 111 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI | 25.2 | 876 | Citations (PDF) |
| 112 | Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial | 3.5 | 10 | Citations (PDF) |
| 113 | Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials | 9.6 | 210 | Citations (PDF) |
| 114 | ST-segment elevation myocardial infarction | 42.5 | 300 | Citations (PDF) |
| 115 | Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. | 7.4 | 534 | Citations (PDF) |
| 116 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk | 13.9 | 645 | Citations (PDF) |
| 117 | Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age | 2.0 | 15 | Citations (PDF) |
| 118 | Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial | 0.9 | 4 | Citations (PDF) |
| 119 | Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention | 3.5 | 28 | Citations (PDF) |
| 120 | Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery Dissection | 1.5 | 88 | Citations (PDF) |
| 121 | Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment: Analysis From the CHAMPION PHOENIX Trial | 3.5 | 0 | Citations (PDF) |
| 122 | Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction. | 6.5 | 31 | Citations (PDF) |
| 123 | Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51 | 3.2 | 13 | Citations (PDF) |
| 124 | Most Promising Therapies in Interventional Cardiology | 2.4 | 14 | Citations (PDF) |
| 125 | Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors | 25.2 | 866 | Citations (PDF) |
| 126 | Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients: An APEX Substudy | 13.9 | 8 | Citations (PDF) |
| 127 | Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy | 5.6 | 19 | Citations (PDF) |
| 128 | Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial | 3.5 | 3 | Citations (PDF) |
| 129 | Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. | 6.5 | 76 | Citations (PDF) |
| 130 | Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial) | 1.5 | 8 | Citations (PDF) |
| 131 | Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis) | 1.5 | 6 | Citations (PDF) |
| 132 | The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction | 1.9 | 40 | Citations (PDF) |
| 133 | Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial | 1.7 | 7 | Citations (PDF) |
| 134 | Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk | 3.1 | 10 | Citations (PDF) |
| 135 | Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial | 5.3 | 63 | Citations (PDF) |
| 136 | Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. | 1.0 | 15 | Citations (PDF) |
| 137 | The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. | 1.0 | 25 | Citations (PDF) |
| 138 | Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis | 1.2 | 54 | Citations (PDF) |
| 139 | Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial | 1.2 | 7 | Citations (PDF) |
| 140 | Saphenous vein grafts in contemporary coronary artery bypass graft surgery | 27.3 | 234 | Citations (PDF) |
| 141 | 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials | 13.9 | 569 | Citations (PDF) |
| 142 | 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials | 6.5 | 291 | Citations (PDF) |
| 143 | Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy | 1.6 | 44 | Citations (PDF) |
| 144 | Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) | 3.5 | 20 | Citations (PDF) |
| 145 | Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy – “Real World” Experience | 5.2 | 9 | Citations (PDF) |
| 146 | Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | 5.2 | 6 | Citations (PDF) |
| 147 | Journal of the American Society of Nephrology | 0.3 | 95 | Citations (PDF) |
| 148 | Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial) | 13.9 | 29 | Citations (PDF) |
| 149 | Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients | 1.9 | 20 | Citations (PDF) |
| 150 | Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study | 1.3 | 8 | Citations (PDF) |
| 151 | Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) | 3.5 | 32 | Citations (PDF) |
| 152 | Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. | 2.0 | 29 | Citations (PDF) |
| 153 | Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. | 1.0 | 8 | Citations (PDF) |
| 154 | Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial | 1.9 | 5 | Citations (PDF) |
| 155 | Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials | 1.7 | 5 | Citations (PDF) |
| 156 | Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial. | 1.0 | 25 | Citations (PDF) |
| 157 | SECURE PCI: how important can a subgroup analysis be? | 1.1 | 1 | Citations (PDF) |
| 158 | Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial | 2.4 | 50 | Citations (PDF) |
| 159 | Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial) | 1.5 | 19 | Citations (PDF) |
| 160 | Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism | 1.2 | 7 | Citations (PDF) |
| 161 | CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction | 2.5 | 19 | Citations (PDF) |
| 162 | Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. | 7.4 | 33 | Citations (PDF) |
| 163 | Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. | 7.4 | 55 | Citations (PDF) |
| 164 | Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention | 1.2 | 11 | Citations (PDF) |
| 165 | Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. | 6.5 | 15 | Citations (PDF) |
| 166 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention | 27.3 | 179 | Citations (PDF) |
| 167 | Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial | 0.9 | 11 | Citations (PDF) |
| 168 | Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update | 13.9 | 200 | Citations (PDF) |
| 169 | Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials | 1.9 | 11 | Citations (PDF) |
| 170 | Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention | 2.0 | 30 | Citations (PDF) |
| 171 | Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry) | 1.5 | 19 | Citations (PDF) |
| 172 | D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy) | 1.5 | 25 | Citations (PDF) |
| 173 | Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial | 1.9 | 8 | Citations (PDF) |
| 174 | Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials | 1.7 | 14 | Citations (PDF) |
| 175 | Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. | 6.5 | 57 | Citations (PDF) |
| 176 | Prevention of Bleeding in Atrial Fibrillation | 25.2 | 1 | Citations (PDF) |
| 177 | Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry | 1.7 | 12 | Citations (PDF) |
| 178 | Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials | 9.6 | 48 | Citations (PDF) |
| 179 | Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials | 1.7 | 24 | Citations (PDF) |
| 180 | Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease | 25.2 | 732 | Citations (PDF) |
| 181 | Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial | 1.9 | 2 | Citations (PDF) |
| 182 | Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis | 1.7 | 25 | Citations (PDF) |
| 183 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | 49.6 | 195 | Citations (PDF) |
| 184 | Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors | 1.2 | 9 | Citations (PDF) |
| 185 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial | 1.9 | 46 | Citations (PDF) |
| 186 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | 3.5 | 6 | Citations (PDF) |
| 187 | Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy | 1.1 | 9 | Citations (PDF) |
| 188 | N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy | 1.2 | 9 | Citations (PDF) |
| 189 | White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry) | 3.5 | 49 | Citations (PDF) |
| 190 | Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX) | 1.5 | 10 | Citations (PDF) |
| 191 | Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy | 3.2 | 39 | Citations (PDF) |
| 192 | Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis | 2.9 | 22 | Citations (PDF) |
| 193 | Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX | 3.5 | 15 | Citations (PDF) |
| 194 | The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification | 0.9 | 121 | Citations (PDF) |
| 195 | Response by Gibson and Fox to Letter Regarding Article, “Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy” | 13.9 | 0 | Citations (PDF) |
| 196 | Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry) | 1.5 | 10 | Citations (PDF) |
| 197 | Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy | 13.9 | 81 | Citations (PDF) |
| 198 | Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban) | 13.9 | 64 | Citations (PDF) |
| 199 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry | 1.3 | 13 | Citations (PDF) |
| 200 | Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study | 2.4 | 10 | Citations (PDF) |
| 201 | Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial | 2.4 | 25 | Citations (PDF) |
| 202 | Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial | 1.2 | 16 | Citations (PDF) |
| 203 | Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database | 1.3 | 6 | Citations (PDF) |
| 204 | Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention | 2.0 | 66 | Citations (PDF) |
| 205 | A Critical Appraisal of Aspirin in Secondary Prevention | 13.9 | 86 | Citations (PDF) |
| 206 | Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction | 13.9 | 183 | Citations (PDF) |
| 207 | Andexanet Alfa for Factor Xa Inhibitor Reversal | 25.2 | 21 | Citations (PDF) |
| 208 | Betrixaban in Acutely Ill Medical Patients | 25.2 | 3 | Citations (PDF) |
| 209 | Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients | 25.2 | 390 | Citations (PDF) |
| 210 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. | 6.5 | 497 | Citations (PDF) |
| 211 | Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy | 3.5 | 12 | Citations (PDF) |
| 212 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study | 1.9 | 105 | Citations (PDF) |
| 213 | Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions | 13.9 | 38 | Citations (PDF) |
| 214 | Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial) | 1.5 | 16 | Citations (PDF) |
| 215 | Sharing Data from Cardiovascular Clinical Trials — A Proposal | 25.2 | 47 | Citations (PDF) |
| 216 | Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. | 6.5 | 105 | Citations (PDF) |
| 217 | Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors | 25.2 | 729 | Citations (PDF) |
| 218 | Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction | 1.9 | 29 | Citations (PDF) |
| 219 | Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial) | 1.5 | 8 | Citations (PDF) |
| 220 | A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease | 1.9 | 19 | Citations (PDF) |
| 221 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. | 2.0 | 47 | Citations (PDF) |
| 222 | Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. | 2.0 | 44 | Citations (PDF) |
| 223 | Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI | 25.2 | 1,343 | Citations (PDF) |
| 224 | Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial | 3.5 | 10 | Citations (PDF) |
| 225 | Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials | 1.3 | 7 | Citations (PDF) |
| 226 | Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention | 13.9 | 30 | Citations (PDF) |
| 227 | Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes | 13.9 | 87 | Citations (PDF) |
| 228 | High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non–ST-segment elevation myocardial infarction | 1.9 | 17 | Citations (PDF) |
| 229 | A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study | 1.9 | 25 | Citations (PDF) |
| 230 | EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. | 7.4 | 147 | Citations (PDF) |
| 231 | The treatment of missing data in a large cardiovascular clinical outcomes study | 1.3 | 16 | Citations (PDF) |
| 232 | The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. | 7.4 | 25 | Citations (PDF) |
| 233 | Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need | 1.8 | 9 | Citations (PDF) |
| 234 | Novel oral anticoagulants and reversal agents: Considerations for clinical development | 1.9 | 63 | Citations (PDF) |
| 235 | Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from the INFUSE-AMI Trial) | 1.5 | 71 | Citations (PDF) |
| 236 | An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI) | 1.9 | 138 | Citations (PDF) |
| 237 | A Living Systematic Review of Nebulized Hypertonic Saline for Acute Bronchiolitis in Infants | 5.0 | 35 | Citations (PDF) |
| 238 | Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb-IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation) | 1.5 | 15 | Citations (PDF) |
| 239 | Usefulness of the Left Anterior Descending Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (an INFUSE-AMI Substudy) | 1.5 | 11 | Citations (PDF) |
| 240 | Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome | 1.2 | 0 | Citations (PDF) |
| 241 | Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). | 2.0 | 34 | Citations (PDF) |
| 242 | The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. | 1.0 | 20 | Citations (PDF) |
| 243 | Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial | 1.9 | 80 | Citations (PDF) |
| 244 | A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial | 1.9 | 44 | Citations (PDF) |
| 245 | Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials | 1.2 | 28 | Citations (PDF) |
| 246 | Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV Trial | 1.9 | 23 | Citations (PDF) |
| 247 | Predictive Value of Admission Platelet Volume Indices for In-hospital Major Adverse Cardiovascular Events in Acute ST-Segment Elevation Myocardial Infarction | 1.5 | 54 | Citations (PDF) |
| 248 | Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: An analysis of Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) | 1.9 | 11 | Citations (PDF) |
| 249 | Angiographic Validation of the American College of Cardiology Foundation–The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies Study | 3.5 | 14 | Citations (PDF) |
| 250 | Clinical Implications and Correlates of Q Waves in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the CLARITY-TIMI 28 Trial | 1.5 | 5 | Citations (PDF) |
| 251 | A Reevaluation of the Costs of Heart Failure and Its Implications for Allocation of Health Resources in the United States | 1.5 | 115 | Citations (PDF) |
| 252 | Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial | 1.0 | 28 | Citations (PDF) |
| 253 | Does Serum Bilirubin Level on Admission Predict TIMI Flow Grade and In-Hospital MACE in Patients With STEMI Undergoing Primary PCI | 1.5 | 44 | Citations (PDF) |
| 254 | Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery: Follow-up From the PREVENT IV Randomized Clinical Trial | 6.3 | 82 | Citations (PDF) |
| 255 | Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. | 1.0 | 49 | Citations (PDF) |
| 256 | Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). | 6.5 | 95 | Citations (PDF) |
| 257 | The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study | 1.9 | 80 | Citations (PDF) |
| 258 | Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: Results from the INFUSE-AMI study | 1.3 | 17 | Citations (PDF) |
| 259 | Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non–ST-Elevation Acute Coronary Syndrome | 1.5 | 16 | Citations (PDF) |
| 260 | Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy | 13.9 | 933 | Citations (PDF) |
| 261 | Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). | 2.0 | 62 | Citations (PDF) |
| 262 | Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery | 13.9 | 193 | Citations (PDF) |
| 263 | Angiographic Outcomes With Early Eptifibatide Therapy in Non–ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial) | 1.5 | 10 | Citations (PDF) |
| 264 | Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. | 7.4 | 68 | Citations (PDF) |
| 265 | A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention: The SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) Trial | 2.0 | 235 | Citations (PDF) |
| 266 | Outcomes in Patients With ST-Segment Elevation Acute Myocardial Infarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial) | 1.5 | 33 | Citations (PDF) |
| 267 | Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes After Coronary Artery Bypass Surgery | 2.4 | 14 | Citations (PDF) |
| 268 | Rationale and design of the AngeLmed for Early Recognition and Treatment of STEMI trial: A randomized, prospective clinical investigation | 1.9 | 8 | Citations (PDF) |
| 269 | Design and rationale of the ANALYZE ST study: A prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients | 1.9 | 5 | Citations (PDF) |
| 270 | Endoscopic Harvesting Device Type and Outcomes in Patients Undergoing Coronary Artery Bypass Surgery | 3.7 | 14 | Citations (PDF) |
| 271 | d-Dimer elevation and adverse outcomes | 1.2 | 105 | Citations (PDF) |
| 272 | Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial | 1.9 | 34 | Citations (PDF) |
| 273 | Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study | 49.6 | 528 | Citations (PDF) |
| 274 | Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting | 1.2 | 13 | Citations (PDF) |
| 275 | Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data | 49.6 | 319 | Citations (PDF) |
| 276 | Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial | 1.9 | 22 | Citations (PDF) |
| 277 | Impact of Hypertension on Distal Embolization, Myocardial Perfusion, and Mortality in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty | 1.5 | 15 | Citations (PDF) |
| 278 | Relation Between White Blood Cell Count and Final Infarct Size in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the INFUSE AMI Trial) | 1.5 | 28 | Citations (PDF) |
| 279 | Relationship Between Myocardial Reperfusion, Infarct Size, and Mortality: The INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) Trial | 2.0 | 41 | Citations (PDF) |
| 280 | Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). | 2.0 | 34 | Citations (PDF) |
| 281 | Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction | 1.9 | 71 | Citations (PDF) |
| 282 | Is There a Need for “Triple Therapy”? Role of Anticoagulation with Dual Antiplatelet Therapy in Acute Coronary Syndromes (ATLAS Study & TRAP Study) | 2.4 | 4 | Citations (PDF) |
| 283 | Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. | 6.5 | 39 | Citations (PDF) |
| 284 | Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges | 1.7 | 71 | Citations (PDF) |
| 285 | Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After Stent Implantation | 0.7 | 0 | Citations (PDF) |
| 286 | Age, treatment, and outcomes in high-risk non‐ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial | 1.7 | 20 | Citations (PDF) |
| 287 | Usefulness of Monocyte Chemoattractant Protein-1 to Predict No-Reflow and Three-Year Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | 1.5 | 13 | Citations (PDF) |
| 288 | Prevalence, Consequences, and Implications for Clinical Trials of Unrecognized Myocardial Infarction | 1.5 | 73 | Citations (PDF) |
| 289 | Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. | 6.5 | 208 | Citations (PDF) |
| 290 | A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trialHeart, 2013, 99, 1282-1287 | 2.8 | 40 | Citations (PDF) |
| 291 | Association of time to reperfusion with left ventricular function and heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: A systematic review | 1.9 | 39 | Citations (PDF) |
| 292 | Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51 | 6.5 | 78 | Citations (PDF) |
| 293 | Obesity and its Association to Phenotype and Clinical Course in Hypertrophic Cardiomyopathy | 6.5 | 165 | Citations (PDF) |
| 294 | Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction | 6.5 | 82 | Citations (PDF) |
| 295 | Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2–TIMI 51) | 1.5 | 33 | Citations (PDF) |
| 296 | Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | 25.2 | 765 | Citations (PDF) |
| 297 | Intralesional Abciximab and Thrombus Aspiration in Patients With Large Anterior Myocardial Infarction: One-Year Results From the INFUSE-AMI Trial | 3.5 | 48 | Citations (PDF) |
| 298 | Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes | 1.2 | 2 | Citations (PDF) |
| 299 | Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial | 1.2 | 13 | Citations (PDF) |
| 300 | Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb–IIIa inhibitors | 0.8 | 16 | Citations (PDF) |
| 301 | Use of Reperfusion Therapies in Elderly Patients with Acute Myocardial Infarction | 2.5 | 0 | Citations (PDF) |
| 302 | Relationship Between Vein Graft Failure and Subsequent Clinical Outcomes After Coronary Artery Bypass Surgery | 13.9 | 147 | Citations (PDF) |
| 303 | Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial | 20.0 | 461 | Citations (PDF) |
| 304 | Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes | 13.9 | 81 | Citations (PDF) |
| 305 | Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy | 2.7 | 152 | Citations (PDF) |
| 306 | A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial | 3.5 | 70 | Citations (PDF) |
| 307 | Admission Hyperglycemia and Acute Myocardial Infarction: Outcomes and Potential Therapies for Diabetics and Nondiabetics | 0.7 | 13 | Citations (PDF) |
| 308 | Optimal selection of STEMI treatment strategies in the current era | 1.1 | 6 | Citations (PDF) |
| 309 | Relation of red cell distribution width with the presence, severity, and complexity of coronary artery disease | 1.2 | 47 | Citations (PDF) |
| 310 | Baseline Platelet Count and Clinical Outcome in Acute Coronary Syndrome | 1.2 | 20 | Citations (PDF) |
| 311 | Patients with tombstoning pattern on the admission electrocardiography who have undergone primary percutaneous coronary intervention for anterior wall ST-elevation myocardial infarction: in-hospital and midterm clinical outcomes. | 0.4 | 2 | Citations (PDF) |
| 312 | Thrombolytics and Myocardial Infarction | 1.2 | 34 | Citations (PDF) |
| 313 | Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction | 1.9 | 97 | Citations (PDF) |
| 314 | Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial | 1.9 | 80 | Citations (PDF) |
| 315 | Relation of Neutrophil/Lymphocyte Ratio to Coronary Flow to In-Hospital Major Adverse Cardiac Events in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Coronary Intervention | 1.5 | 180 | Citations (PDF) |
| 316 | Newer Pharmaceutical Agents for STEMI Interventions | 0.7 | 0 | Citations (PDF) |
| 317 | Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. | 2.0 | 18 | Citations (PDF) |
| 318 | Significance of False Negative Electrocardiograms in Preparticipation Screening of Athletes for Hypertrophic Cardiomyopathy | 1.5 | 93 | Citations (PDF) |
| 319 | Atherosclerotic Risk Factors and Their Association With Hospital Mortality Among Patients With First Myocardial Infarction (from the National Registry of Myocardial Infarction) | 1.5 | 38 | Citations (PDF) |
| 320 | Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes | 2.6 | 3 | Citations (PDF) |
| 321 | Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | 25.2 | 1,633 | Citations (PDF) |
| 322 | Intermediate-Signal-Intensity Late Gadolinium Enhancement Predicts Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy | 2.7 | 68 | Citations (PDF) |
| 323 | Prognostic Value of Uric Acid in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Coronary Intervention | 1.5 | 90 | Citations (PDF) |
| 324 | Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention†‡ | 1.3 | 28 | Citations (PDF) |
| 325 | Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy | 1.2 | 9 | Citations (PDF) |
| 326 | RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. | 7.4 | 156 | Citations (PDF) |
| 327 | Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies. | 0.3 | 38 | Citations (PDF) |
| 328 | Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction | 1.9 | 32 | Citations (PDF) |
| 329 | Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome | 1.9 | 80 | Citations (PDF) |
| 330 | Association of initial Thrombolysis in Myocardial Infarction flow grade with mortality among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A National Registry of Myocardial Infarction-5 (NRMI-5) analysis | 1.9 | 11 | Citations (PDF) |
| 331 | Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction | 1.2 | 37 | Citations (PDF) |
| 332 | Red cell distribution width as a novel prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction | 1.2 | 124 | Citations (PDF) |
| 333 | Relation of Circulating Osteoprotegerin Levels on Admission to Microvascular Obstruction After Primary Percutaneous Coronary Intervention | 1.5 | 10 | Citations (PDF) |
| 334 | Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis | 1.2 | 7 | Citations (PDF) |
| 335 | Coronary flow reserve varies depending upon the location within the artery it is assessed and the TIMI myocardial perfusion grade: a PROTECT TIMI-30 analysis | 1.2 | 0 | Citations (PDF) |
| 336 | Percutaneous Coronary Interventions in Facilities Without Cardiac Surgery on Site | 2.4 | 2 | Citations (PDF) |
| 337 | Intracoronary delivery of eptifibatide with the ClearWay® RX infusion catheter† | 1.3 | 2 | Citations (PDF) |
| 338 | Hypertrophic Cardiomyopathy: Quantification of Late Gadolinium Enhancement with Contrast-enhanced Cardiovascular MR Imaging | 7.2 | 157 | Citations (PDF) |
| 339 | Number of Coronary Heart Disease Risk Factors and Mortality in Patients With First Myocardial Infarction | 20.0 | 192 | Citations (PDF) |
| 340 | Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium | 13.9 | 3,949 | Citations (PDF) |
| 341 | Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy | 13.9 | 382 | Citations (PDF) |
| 342 | Saphenous Vein Grafts With Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial | 13.9 | 112 | Citations (PDF) |
| 343 | Benefit of Transferring ST-Segment–Elevation Myocardial Infarction Patients for Percutaneous Coronary Intervention Compared With Administration of Onsite Fibrinolytic Declines as Delays Increase | 13.9 | 147 | Citations (PDF) |
| 344 | Intensive statin therapy: a goal worth targeting | 0.0 | 0 | Citations (PDF) |
| 345 | Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb–IIIa inhibitors: insights from the EGYPT cooperation | 1.2 | 40 | Citations (PDF) |
| 346 | Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes | 1.2 | 6 | Citations (PDF) |
| 347 | Spectrum and Clinical Significance of Systolic Function and Myocardial Fibrosis Assessed by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy | 1.5 | 147 | Citations (PDF) |
| 348 | Relation Between Infarct Size in ST-Segment Elevation Myocardial Infarction Treated Successfully by Percutaneous Coronary Intervention and Left Ventricular Ejection Fraction Three Months After the Infarct | 1.5 | 29 | Citations (PDF) |
| 349 | Adjunctive transcutaneous ultrasound with thrombolysis: results of the PLUS (Perfusion by ThromboLytic and UltraSound) trial. | 2.0 | 20 | Citations (PDF) |
| 350 | Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. | 2.0 | 88 | Citations (PDF) |
| 351 | Incremental Benefit of 80-Lead Electrocardiogram Body Surface Mapping Over the 12-Lead Electrocardiogram in the Detection of Acute Coronary Syndromes in Patients Without ST-elevation Myocardial Infarction: Results from the Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction (OCCULT MI) Trial | 1.3 | 13 | Citations (PDF) |
| 352 | Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function: The Intracoronary Eptifibatide (ICE) Trial | 13.9 | 88 | Citations (PDF) |
| 353 | Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. | 7.4 | 33 | Citations (PDF) |
| 354 | Initial clinical results using intracardiac electrogram monitoring to detect and alert patients during coronary plaque rupture and ischemia. | 6.5 | 42 | Citations (PDF) |
| 355 | Diagnostic accuracy of 64-slice multidetector CT for detection of in-stent restenosis in an unselected, consecutive patient population | 2.2 | 29 | Citations (PDF) |
| 356 | Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI) | 1.9 | 63 | Citations (PDF) |
| 357 | Intravenous Platelet Blockade with Cangrelor during PCI | 25.2 | 589 | Citations (PDF) |
| 358 | Platelet Inhibition with Cangrelor in Patients Undergoing PCI | 25.2 | 557 | Citations (PDF) |
| 359 | Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. | 7.4 | 163 | Citations (PDF) |
| 360 | Endoscopic versus Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery | 25.2 | 329 | Citations (PDF) |
| 361 | Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial | 3.5 | 23 | Citations (PDF) |
| 362 | Outcomes Among Patients With ST-Segment–Elevation Myocardial Infarction Presenting to Interventional Hospitals With and Without On-Site Cardiac Surgery | 3.1 | 33 | Citations (PDF) |
| 363 | Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study) | 1.5 | 33 | Citations (PDF) |
| 364 | Predicting Irreversible Left Ventricular Dysfunction After Acute Myocardial Infarction | 1.5 | 8 | Citations (PDF) |
| 365 | Timing and Duration of Myocardial Ischemia on Holter Monitoring Following Percutaneous Coronary Intervention and Their Association With Clinical Outcomes (a PROTECT-TIMI 30 Substudy Analysis) | 1.5 | 4 | Citations (PDF) |
| 366 | Relation Between Myocardial Infarct Size and Ventricular Tachyarrhythmia Among Patients With Preserved Left Ventricular Ejection Fraction Following Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction | 1.5 | 20 | Citations (PDF) |
| 367 | Outcomes among patients with non-ST-segment elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery. | 2.0 | 16 | Citations (PDF) |
| 368 | Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography | 1.9 | 138 | Citations (PDF) |
| 369 | Association of Thrombolysis in Myocardial Infarction Myocardial Perfusion Grade with cardiovascular magnetic resonance measures of infarct architecture after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction | 1.9 | 19 | Citations (PDF) |
| 370 | Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)–Thrombolysis in Myocardial Infarction (TIMI) 38 Substudy | 1.9 | 29 | Citations (PDF) |
| 371 | Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors | 1.9 | 23 | Citations (PDF) |
| 372 | Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes | 1.3 | 2 | Citations (PDF) |
| 373 | Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance | 6.5 | 429 | Citations (PDF) |
| 374 | Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. | 6.5 | 108 | Citations (PDF) |
| 375 | Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors | 1.9 | 85 | Citations (PDF) |
| 376 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial | 49.6 | 915 | Citations (PDF) |
| 377 | Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors: insights from the EGYPT cooperation | 1.2 | 13 | Citations (PDF) |
| 378 | Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction | 1.2 | 17 | Citations (PDF) |
| 379 | Antiplatelet therapy: anti-ischemic benefits versus bleeding risk. | 0.4 | 3 | Citations (PDF) |
| 380 | Association of Blood Glucose With Angiographic and Clinical Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction (from the CLARITY-TIMI-28 Study) | 1.5 | 58 | Citations (PDF) |
| 381 | Significance of Papillary Muscle Abnormalities Identified by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy | 1.5 | 140 | Citations (PDF) |
| 382 | Relation of Hyperemic Epicardial Flow to Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy | 1.5 | 7 | Citations (PDF) |
| 383 | Impact of Perioperative Myocardial Infarction on Angiographic and Clinical Outcomes Following Coronary Artery Bypass Grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV) | 1.5 | 58 | Citations (PDF) |
| 384 | Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery | 2.2 | 20 | Citations (PDF) |
| 385 | Association of Impaired Thrombolysis In Myocardial Infarction Myocardial Perfusion Grade With Ventricular Tachycardia and Ventricular Fibrillation Following Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction | 6.5 | 28 | Citations (PDF) |
| 386 | Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. | 6.5 | 570 | Citations (PDF) |
| 387 | The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes | 1.7 | 4 | Citations (PDF) |
| 388 | Coronary Artery Bypass Graft Failure After On-Pump and Off-Pump Coronary Artery Bypass: Findings From PREVENT IV | 2.4 | 103 | Citations (PDF) |
| 389 | Impact of Saphenous Vein Graft Radiographic Markers on Clinical Events and Angiographic Parameters | 2.4 | 8 | Citations (PDF) |
| 390 | Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: A Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study | 1.9 | 10 | Citations (PDF) |
| 391 | Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: Results of a multicenter case-control study with 145 thrombosis events | 1.9 | 27 | Citations (PDF) |
| 392 | Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006 | 1.9 | 218 | Citations (PDF) |
| 393 | Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006 | 1.9 | 221 | Citations (PDF) |
| 394 | Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006 | 1.9 | 341 | Citations (PDF) |
| 395 | Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. | 7.4 | 45 | Citations (PDF) |
| 396 | Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy | 3.0 | 276 | Citations (PDF) |
| 397 | Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction | 13.9 | 174 | Citations (PDF) |
| 398 | Association of TIMI Myocardial Perfusion Grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction | 1.2 | 27 | Citations (PDF) |
| 399 | Association of angiographic perfusion score following percutaneous coronary intervention for ST-elevation myocardial infarction with left ventricular remodeling at 6 weeks in GRACIA-2 | 1.2 | 6 | Citations (PDF) |
| 400 | Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years | 1.2 | 46 | Citations (PDF) |
| 401 | Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis | 1.2 | 18 | Citations (PDF) |
| 402 | Transfusion associated microchimerism: a heretofore little recognized complication following transfusion | 1.2 | 7 | Citations (PDF) |
| 403 | Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation | 1.2 | 12 | Citations (PDF) |
| 404 | Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. | 7.4 | 130 | Citations (PDF) |
| 405 | Diagnostic and Prognostic Utility of Brain Natriuretic Peptide in Subjects Admitted to the ICU With Hypoxic Respiratory Failure Due to Noncardiogenic and Cardiogenic Pulmonary EdemaChest, 2007, 131, 964-971 | 0.9 | 115 | Citations (PDF) |
| 406 | Temporal changes in TIMI myocardial perfusion grade in relation to epicardial flow, ST-resolution and left ventricular function after primary percutaneous coronary intervention | 1.2 | 6 | Citations (PDF) |
| 407 | Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. | 7.4 | 55 | Citations (PDF) |
| 408 | Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial | 1.9 | 15 | Citations (PDF) |
| 409 | Preliminary experience with intravenous P2Y platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial | 1.9 | 61 | Citations (PDF) |
| 410 | Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery | 2.4 | 75 | Citations (PDF) |
| 411 | Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. | 7.4 | 165 | Citations (PDF) |
| 412 | Enoxaparin in acute coronary syndromes | 1.2 | 14 | Citations (PDF) |
| 413 | Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. | 6.5 | 103 | Citations (PDF) |
| 414 | Delayed-Enhancement Cardiovascular Magnetic Resonance Coronary Artery Wall Imaging | 6.5 | 103 | Citations (PDF) |
| 415 | Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes | 25.2 | 5,931 | Citations (PDF) |
| 416 | Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial | 1.3 | 10 | Citations (PDF) |
| 417 | Timing of Glycoprotein IIb/IIIa Inhibitor Use and Outcomes Among Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (Results from CRUSADE) | 1.5 | 23 | Citations (PDF) |
| 418 | Association of Prerandomization Anticoagulant Switching With Bleeding in the Setting of Percutaneous Coronary Intervention (A REPLACE-2 Analysis) | 1.5 | 22 | Citations (PDF) |
| 419 | Impact of Iodinated Contrast Injections on Percent Diameter Coronary Arterial Stenosis and Implications for Trials of Intracoronary Pharmacotherapies in Patients With ST-Elevation Myocardial Infarction | 1.5 | 2 | Citations (PDF) |
| 420 | Effect of Thrombocytopenia on Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting With Acute Coronary Syndromes | 1.5 | 23 | Citations (PDF) |
| 421 | Reperfusion strategies for ST-elevation myocardial infarction | 2.4 | 7 | Citations (PDF) |
| 422 | Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review | 1.2 | 30 | Citations (PDF) |
| 423 | Advances in antithrombin and antiplatelet therapy for percutaneous coronary intervention | 1.2 | 0 | Citations (PDF) |
| 424 | Vascular endothelial growth factors in pulmonary edema: an update | 1.2 | 30 | Citations (PDF) |
| 425 | Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days | 1.2 | 3 | Citations (PDF) |
| 426 | Coronary Angiography: Beyond Coronary Anatomy | 0.5 | 1 | Citations (PDF) |
| 427 | Coronariografía: más allá de la anatomía coronaria | 0.9 | 5 | Citations (PDF) |
| 428 | Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide: Observations From the PROTECT–TIMI-30 Trial | 6.5 | 103 | Citations (PDF) |
| 429 | A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. | 6.5 | 113 | Citations (PDF) |
| 430 | The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction: The ECG CLARITY–TIMI 28 Study | 6.5 | 51 | Citations (PDF) |
| 431 | Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial | 1.9 | 82 | Citations (PDF) |
| 432 | Distal Embolization of Thrombus in Acute Myocardial Infarction | 1.6 | 177 | Citations (PDF) |
| 433 | Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non–ST-elevation myocardial infarction | 1.9 | 19 | Citations (PDF) |
| 434 | Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: The Swedish Early Decision (SWEDES) reperfusion trial | 1.9 | 27 | Citations (PDF) |
| 435 | Prevalence, predictors, and outcomes of patients with non–ST-segment elevation myocardial infarction and insignificant coronary artery disease: Results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative | 1.9 | 175 | Citations (PDF) |
| 436 | Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction | 1.9 | 11 | Citations (PDF) |
| 437 | Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) | 1.9 | 277 | Citations (PDF) |
| 438 | Association between Thrombolysis In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: Observations from the Randomized Trial to Evaluate the Relative ion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic Agents–Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) | 1.9 | 29 | Citations (PDF) |
| 439 | Association of a History of Systemic Hypertension With Mortality, Thrombotic, and Bleeding Complications Following Non-ST-Segment Elevation Acute Coronary Syndrome | 1.6 | 24 | Citations (PDF) |
| 440 | Early Invasive Strategy Improves Outcomes in Patients With Acute Coronary Syndrome With Previous Coronary Artery Bypass Graft Surgery | 0.6 | 25 | Citations (PDF) |
| 441 | Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina | 1.2 | 26 | Citations (PDF) |
| 442 | Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial | 1.2 | 4 | Citations (PDF) |
| 443 | Comparison of Effects of Bare Metal Versus Drug-Eluting Stent Implantation on Biomarker Levels Following Percutaneous Coronary Intervention for Non–ST-Elevation Acute Coronary Syndrome | 1.5 | 31 | Citations (PDF) |
| 444 | Association Between Blood Glucose and Long-Term Mortality in Patients With Acute Coronary Syndromes in the OPUS-TIMI 16 Trial | 1.5 | 39 | Citations (PDF) |
| 445 | Association of Platelet Counts on Presentation and Clinical Outcomes in ST-Elevation Myocardial Infarction (from the TIMI Trials) | 1.5 | 72 | Citations (PDF) |
| 446 | Usefulness of Clopidogrel in Abolishing the Increased Risk of Reinfarction Associated With Higher Platelet Counts in Patients With ST-Elevation Myocardial Infarction (Results from CLARITY-TIMI 28) | 1.5 | 18 | Citations (PDF) |
| 447 | Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. | 7.4 | 56 | Citations (PDF) |
| 448 | Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. | 7.4 | 15 | Citations (PDF) |
| 449 | The association of impaired myocardial perfusion and monocytosis with late recovery of left ventricular function following primary percutaneous coronary intervention. | 7.4 | 4 | Citations (PDF) |
| 450 | Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction: Implications When Selecting a Reperfusion Strategy | 13.9 | 437 | Citations (PDF) |
| 451 | Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded | 7.7 | 388 | Citations (PDF) |
| 452 | Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction | 1.5 | 3 | Citations (PDF) |
| 453 | Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy | 1.5 | 4 | Citations (PDF) |
| 454 | C-Reactive Protein and Cardiovascular Outcomes in Smokers Versus Nonsmokers in Non–ST-Elevation Acute Coronary Syndrome (from the TACTICS-TIMI 18 Trial) | 1.5 | 6 | Citations (PDF) |
| 455 | Outcome in Patients Transferred for Percutaneous Coronary Intervention (A National Registry of Myocardial Infarction 2/3/4 Analysis) | 1.5 | 44 | Citations (PDF) |
| 456 | Administration of Intracoronary Eptifibatide During ST-Elevation Myocardial Infarction | 1.5 | 16 | Citations (PDF) |
| 457 | Current assessments of the adequacy of myocardial perfusion during acute MI | 0.7 | 0 | Citations (PDF) |
| 458 | Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes | 13.9 | 628 | Citations (PDF) |
| 459 | Influence of Race on Death and Ischemic Complications in Patients With Non–ST-Elevation Acute Coronary Syndromes Despite Modern, Protocol-Guided Treatment | 13.9 | 55 | Citations (PDF) |
| 460 | Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non–ST-Segment Elevation Acute Coronary Syndromes | 20.0 | 554 | Citations (PDF) |
| 461 | Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics: The PCI-CLARITY Study | 20.0 | 602 | Citations (PDF) |
| 462 | Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. | 7.4 | 48 | Citations (PDF) |
| 463 | Correlation between the TIMI risk score and high-risk angiographic findings in non–ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial | 1.9 | 53 | Citations (PDF) |
| 464 | Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial | 1.9 | 45 | Citations (PDF) |
| 465 | Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: Results of a randomized trial | 1.9 | 9 | Citations (PDF) |
| 466 | A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study) | 1.9 | 69 | Citations (PDF) |
| 467 | The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale | 1.9 | 80 | Citations (PDF) |
| 468 | The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial | 1.9 | 53 | Citations (PDF) |
| 469 | Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. | 6.5 | 13 | Citations (PDF) |
| 470 | Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. | 6.5 | 126 | Citations (PDF) |
| 471 | Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. | 6.5 | 106 | Citations (PDF) |
| 472 | Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation | 25.2 | 1,600 | Citations (PDF) |
| 473 | Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. | 7.4 | 112 | Citations (PDF) |
| 474 | Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment–Elevation Myocardial Infarction | 13.9 | 41 | Citations (PDF) |
| 475 | Coronary and Myocardial Angiography: Angiographic Assessment of Both Epicardial and Myocardial Perfusion | 13.9 | 134 | Citations (PDF) |
| 476 | Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis In Myocardial Infarction 18) Substudy | 13.9 | 163 | Citations (PDF) |
| 477 | Time is muscle in primary PCI: the strength of the evidence grows. | 7.4 | 27 | Citations (PDF) |
| 478 | Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. | 7.4 | 26 | Citations (PDF) |
| 479 | Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative | 20.0 | 494 | Citations (PDF) |
| 480 | The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. | 7.4 | 20 | Citations (PDF) |
| 481 | Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. | 0.4 | 24 | Citations (PDF) |
| 482 | Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction | 1.5 | 79 | Citations (PDF) |
| 483 | Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion | 1.5 | 48 | Citations (PDF) |
| 484 | Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction | 1.5 | 4 | Citations (PDF) |
| 485 | Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries | 1.5 | 11 | Citations (PDF) |
| 486 | Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy) | 1.5 | 16 | Citations (PDF) |
| 487 | Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction | 1.5 | 6 | Citations (PDF) |
| 488 | Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction | 1.5 | 30 | Citations (PDF) |
| 489 | Safety of stress testing during the evolution of unstable angina pectoris or non–ST-elevation myocardial infarction | 1.5 | 7 | Citations (PDF) |
| 490 | Association of Epicardial and Tissue-Level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction | 1.2 | 28 | Citations (PDF) |
| 491 | Door-to-balloon delays with PCI in acute myocardial infarction | 0.7 | 4 | Citations (PDF) |
| 492 | Myonecrosis following stent placement: Association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction | 1.3 | 39 | Citations (PDF) |
| 493 | Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. | 6.5 | 23 | Citations (PDF) |
| 494 | Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. | 6.5 | 7 | Citations (PDF) |
| 495 | Association of Elevated B-Type Natriuretic Peptide Levels With Angiographic Findings Among Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction | 6.5 | 96 | Citations (PDF) |
| 496 | A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. | 6.5 | 44 | Citations (PDF) |
| 497 | B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. | 6.5 | 177 | Citations (PDF) |
| 498 | Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. | 6.5 | 45 | Citations (PDF) |
| 499 | Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. | 6.5 | 39 | Citations (PDF) |
| 500 | Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction | 1.9 | 25 | Citations (PDF) |
| 501 | Angiographic perfusion score: An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction | 1.9 | 67 | Citations (PDF) |
| 502 | NRMI and current treatment patterns for ST-elevation myocardial infarction | 1.9 | 60 | Citations (PDF) |
| 503 | Greater Benefit of Early Invasive Strategy for Unstable Angina and Non-ST Elevation Myocardial Infarction in United States Compared With Non-United States Patients | 0.6 | 0 | Citations (PDF) |
| 504 | Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4A simple index that predicts mortality in ST-segment elevation myocardial infarction | 6.5 | 73 | Citations (PDF) |
| 505 | Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion | 1.5 | 2 | Citations (PDF) |
| 506 | Distance from the Coronary Ostium to the Culprit Lesion in Acute ST-Elevation Myocardial Infarction and its Implications Regarding the Potential Prevention of Proximal Plaque Rupture | 1.2 | 41 | Citations (PDF) |
| 507 | The Prognostic Value of Serum Creatinine on Admission in Fibrinolytic-Eligible Patients with Acute Myocardial Infarction | 1.2 | 18 | Citations (PDF) |
| 508 | Meta-analysis of corticosteroid treatment in acute myocardial infarction | 1.5 | 163 | Citations (PDF) |
| 509 | Time for contrast material to traverse the epicardial artery and the myocardium in ST-Segment elevation acute myocardial infarction versus unstable angina pectoris/non–ST-elevation acute myocardial infarction | 1.5 | 11 | Citations (PDF) |
| 510 | Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction | 1.5 | 21 | Citations (PDF) |
| 511 | Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction | 1.5 | 62 | Citations (PDF) |
| 512 | Diminution in flow following primary stenting in the INAMI study | 1.3 | 0 | Citations (PDF) |
| 513 | Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality | 6.5 | 211 | Citations (PDF) |
| 514 | Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. | 6.5 | 86 | Citations (PDF) |
| 515 | Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non–ST-elevation myocardial infarction | 6.5 | 356 | Citations (PDF) |
| 516 | Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. | 6.5 | 155 | Citations (PDF) |
| 517 | Angiographic and clinical characteristics associated with the development of q-wave and non-q–wave myocardial infarction in the thrombolysis in myocardial infarction (timi) 14 trial | 1.9 | 4 | Citations (PDF) |
| 518 | Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry | 1.9 | 52 | Citations (PDF) |
| 519 | The VIVA Trial | 13.9 | 931 | Citations (PDF) |
| 520 | Safety and efficacy of tenecteplase in acute myocardial infarction | 1.9 | 16 | Citations (PDF) |
| 521 | Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock | 13.9 | 128 | Citations (PDF) |
| 522 | Has My Patient Achieved Adequate Myocardial Reperfusion? | 13.9 | 31 | Citations (PDF) |
| 523 | Soluble CD40L: Risk Prediction After Acute Coronary Syndromes | 13.9 | 355 | Citations (PDF) |
| 524 | Myocardial Reperfusion: Its Assessment and Its Relation to Clinical Outcomes | 0.1 | 3 | Citations (PDF) |
| 525 | Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes | 13.9 | 420 | Citations (PDF) |
| 526 | Safety and efficacy of tenecteplase in acute myocardial infarction | 1.9 | 0 | Citations (PDF) |
| 527 | Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide | 13.9 | 660 | Citations (PDF) |
| 528 | Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction | 13.9 | 339 | Citations (PDF) |
| 529 | Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial | 13.9 | 214 | Citations (PDF) |
| 530 | Elevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion: A TACTICS-TIMI 18 Substudy | 13.9 | 114 | Citations (PDF) |
| 531 | Outcome of Patients With Acute Coronary Syndrome Admitted to Hospitals With or Without Onsite Cardiac Catheterization Laboratory | 0.6 | 4 | Citations (PDF) |
| 532 | Critical Pathway for Acute ST-Segment Elevation Myocardial Infarction | 0.6 | 2 | Citations (PDF) |
| 533 | The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. | 6.5 | 51 | Citations (PDF) |
| 534 | Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. | 6.5 | 219 | Citations (PDF) |
| 535 | Elevated C Reactive Protein (CRP) is associated with a higher risk of thrombotic occlusion and poorer flow following percutaneous coronary intervention in patients with acute coronary syndromes: a TACTICS TIMI 18 angiographic substudy | 6.5 | 2 | Citations (PDF) |
| 536 | Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: An ESPRIT substudy | 1.9 | 36 | Citations (PDF) |
| 537 | Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes | 1.9 | 160 | Citations (PDF) |
| 538 | Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial | 1.9 | 34 | Citations (PDF) |
| 539 | Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy | 1.9 | 22 | Citations (PDF) |
| 540 | Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy | 2.5 | 11 | Citations (PDF) |
| 541 | Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy | 1.9 | 45 | Citations (PDF) |
| 542 | Predictors of door-to-balloon delay in primary angioplasty | 1.5 | 134 | Citations (PDF) |
| 543 | Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction | 1.5 | 13 | Citations (PDF) |
| 544 | Intra-aortic balloon pump placement following aorto-iliac angioplasty and stent placement | 1.3 | 10 | Citations (PDF) |
| 545 | Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention | 1.3 | 36 | Citations (PDF) |
| 546 | Precordial ST-Segment Depression in Inferior Myocardial Infarction is Associated with Slow Flow in the Non-Culprit Left Anterior Descending Artery | 1.2 | 7 | Citations (PDF) |
| 547 | The Relationship of Intracoronary Stent Placement Following Thrombolytic Therapy to Tissue Level Perfusion | 1.2 | 1 | Citations (PDF) |
| 548 | The Smoker's Paradox: Insights from the Angiographic Substudies of the TIMI Trials | 1.2 | 49 | Citations (PDF) |
| 549 | Methodologic and Clinical Validation of the TIMI Myocardial Perfusion Grade in Acute Myocardial Infarction | 1.2 | 22 | Citations (PDF) |
| 550 | Quantitative Comparison of Coronary Artery Flow and Myocardial Perfusion in Patients with Acute Myocardial Infarction in the Presence and Absence of Recent Cocaine Use | 1.2 | 17 | Citations (PDF) |
| 551 | Minimal ST-segment deviation: A simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration | 1.9 | 16 | Citations (PDF) |
| 552 | Minimal ST-segment deviation: A simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration | 1.9 | 0 | Citations (PDF) |
| 553 | Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. | 6.5 | 55 | Citations (PDF) |
| 554 | Determination of a weight-adjusted dose of TNK–tissue plasminogen activator | 1.9 | 16 | Citations (PDF) |
| 555 | Preserved coronary flow reserve in viable myocardium: Further evidence for the microvascular hypothesis | 1.9 | 0 | Citations (PDF) |
| 556 | Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial | 1.9 | 33 | Citations (PDF) |
| 557 | Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis) | 1.9 | 15 | Citations (PDF) |
| 558 | Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban | 25.2 | 1,794 | Citations (PDF) |
| 559 | Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction | 1.3 | 8 | Citations (PDF) |
| 560 | Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA) | 1.5 | 17 | Citations (PDF) |
| 561 | Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? | 1.5 | 6 | Citations (PDF) |
| 562 | Effect of eptifibatide on coronary flow reserve following coronary stent implantation (An ESPRIT substudy) | 1.5 | 36 | Citations (PDF) |
| 563 | Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B–TIMI 14 experience) | 1.5 | 46 | Citations (PDF) |
| 564 | Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial | 1.5 | 17 | Citations (PDF) |
| 565 | Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials | 1.3 | 15 | Citations (PDF) |
| 566 | St-segment resolution and infarct-related artery patency and flow after thrombolytic therapy | 1.5 | 188 | Citations (PDF) |
| 567 | Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials) | 1.5 | 17 | Citations (PDF) |
| 568 | Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. | 1.5 | 96 | Citations (PDF) |
| 569 | Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting | 1.5 | 149 | Citations (PDF) |
| 570 | Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy) | 1.5 | 15 | Citations (PDF) |
| 571 | References on a Wide Variety of Topics Pertaining to Coronary Artery Blood Flow and Patency | 1.2 | 0 | Citations (PDF) |
| 572 | Relationship of Symptom-Onset-to-Balloon Time and Door-to-Balloon Time With Mortality in Patients Undergoing Angioplasty for Acute Myocardial Infarction | 20.0 | 984 | Citations (PDF) |
| 573 | Glycoprotein IIb/IIIa Receptor Inhibition in Interventional Cardiology | 1.2 | 1 | Citations (PDF) |
| 574 | Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. | 6.5 | 59 | Citations (PDF) |
| 575 | Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. | 6.5 | 131 | Citations (PDF) |
| 576 | The Open Artery Hypothesis: Past, Present, and Future | 1.2 | 3 | Citations (PDF) |
| 577 | Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis | 1.5 | 92 | Citations (PDF) |
| 578 | Coronary artery injection technique: A quantitative in vivo investigation using modern catheters | 0.9 | 7 | Citations (PDF) |
| 579 | Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. | 6.5 | 82 | Citations (PDF) |
| 580 | Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: Results from TIMI 10A | 1.9 | 35 | Citations (PDF) |
| 581 | Relation between injections before 90-minute angiography and coronary patency: Results of the Thrombolysis in Myocardial Infarction 4 Trial* | 1.9 | 5 | Citations (PDF) |
| 582 | Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. | 1.5 | 83 | Citations (PDF) |
| 583 | TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-Ranging Trial | 13.9 | 202 | Citations (PDF) |
| 584 | Is gender an independent predictor of angiographic & adverse outcomes following thrombolysis? | 6.5 | 0 | Citations (PDF) |
| 585 | Variation between hospitals in coronary angiographic interpretations in the medicare heart bypass center demonstration. Implications for CABG surgery rates | 6.5 | 0 | Citations (PDF) |
| 586 | Effect of Combination Therapy with Lipid-Reducing Drugs in Patients with Coronary Heart Disease and “Normal” Cholesterol Levels: A Randomized, Placebo-Controlled Trial | 7.7 | 69 | Citations (PDF) |
| 587 | Techniques in the Angiographic Analysis of Coronary Flow: Past, Present, and Future | 0.4 | 16 | Citations (PDF) |
| 588 | TIMI Frame Count : A Quantitative Method of Assessing Coronary Artery Flow | 13.9 | 1,461 | Citations (PDF) |
| 589 | Angiographic predictors of reocclusion after thrombolysis: Results from the thrombolysis in myocardial infarction (TIMI) 4 trial | 6.5 | 56 | Citations (PDF) |
| 590 | Controlled trial of fish oil for regression of human coronary atherosclerosis | 6.5 | 180 | Citations (PDF) |
| 591 | Previous Angina Alters In-Hospital Outcome in TIMI 4 : A Clinical Correlate to Preconditioning? | 13.9 | 430 | Citations (PDF) |
| 592 | Is 40% to 70% diameter narrowing at the site of previous stenting or directional coronary atherectomy clinically significant? | 1.5 | 29 | Citations (PDF) |
| 593 | Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patients | 1.9 | 86 | Citations (PDF) |
| 594 | Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients | 49.6 | 157 | Citations (PDF) |
| 595 | Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression | 1.5 | 29 | Citations (PDF) |
| 596 | Mechanisms of restenosis and redilation within coronary stents—Quantitative angiographic assessment | 6.5 | 205 | Citations (PDF) |
| 597 | Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy | 6.5 | 470 | Citations (PDF) |
| 598 | Angiographic and clinical outcome of intracoronary stenting: Immediate and long-term results from a large single-center experience | 6.5 | 269 | Citations (PDF) |
| 599 | Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials | 1.5 | 86 | Citations (PDF) |
| 600 | Limitations of cineangiography | 5.1 | 2 | Citations (PDF) |
| 601 | Atrial Fibrillation Induced by Breath Spray | 25.2 | 10 | Citations (PDF) |
| 602 | The Cochrane Library | 3.3 | 1 | Citations (PDF) |
| 603 | The Cochrane Library | 3.3 | 1 | Citations (PDF) |
| 604 | The Relationship Between the Age of First Acute Coronary Syndrome Episode and Internal Migration. | 0.2 | 1 | Citations (PDF) |
| 605 | Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism | 27.3 | 44 | Citations (PDF) |
| 606 | Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis Open Access | 2.7 | 18 | Citations (PDF) |
| 607 | Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT Open Access | 1.6 | 3 | Citations (PDF) |
| 608 | Response by Jaber et al to Letter Regarding Article, “Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial” | 13.9 | 8 | Citations (PDF) |
| 609 | Reduced vs full-dose direct oral anticoagulants for extended treatment of cancer-associated venous thromboembolism: a systematic review and meta-analysis of randomized trials. | 2.9 | 4 | Citations (PDF) |
| 610 | Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? Available for Purchase | 7.4 | 21 | Citations (PDF) |
| 611 | Minimizing Missing Data in Clinical Trials | 13.9 | 5 | Citations (PDF) |
| 612 | Mass balance and metabolite profiling of 14C-Zalunfiban in humans following single-dose subcutaneous administration | 1.0 | 2 | Citations (PDF) |
| 613 | Sex Differences in Spontaneous Coronary Artery Dissection: A Report of the iSCAD Registry | 3.2 | 5 | Citations (PDF) |
| 614 | Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies | 27.3 | 31 | Citations (PDF) |
| 615 | Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management Open Access | 2.7 | 2 | Citations (PDF) |
| 616 | Angiography-Derived Microvascular Resistance: Elegant Theory, Elusive Accuracy. | 2.0 | 0 | Citations (PDF) |
| 617 | 26-A-14586-ACC ENHANCED EXTERNAL COUNTERPULSATION IN THE MANAGEMENT OF CHRONIC CORONARY DISEASE | 6.5 | 0 | Citations (PDF) |
| 618 | 26-A-13454-ACC TIME TO SUSTAINED CARDIOVASCULAR BENEFIT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN HIGH-RISK PATIENTS: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS | 6.5 | 0 | Citations (PDF) |
| 619 | 26-A-20143-ACC LIPOPROTEIN(A) AND SUBSEQUENT CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-ST ELEVATION MYOCARDIAL INFARCTION: A REAL-WORLD ANALYSIS FROM THE TRINETX COLLABORATIVE NETWORK | 6.5 | 0 | Citations (PDF) |
| 620 | Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network. | 1.3 | 4 | Citations (PDF) |
| 621 | Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences. | 7.4 | 7 | Citations (PDF) |
| 622 | The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI. | 1.9 | 0 | Citations (PDF) |
| 623 | Exploratory LC-MS/MS-Based Proteomic and Lipidomic Profiling of Plasma Samples from Premature Coronary Artery Disease Patients: A Pilot Study in a South Asian Population. | 3.3 | 0 | Citations (PDF) |
| 624 | Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. | 6.5 | 1 | Citations (PDF) |
| 625 | Sodium-Glucose Cotransporter-2 Inhibitors in Valvular Heart Disease: From Mechanistic Insights to Clinical Application. | 1.2 | 0 | Citations (PDF) |
| 626 | The role of biomarkers across the care continuum in acute heart failure. | 7.4 | 0 | Citations (PDF) |
| 627 | Intracoronary Low-Dose Thrombolysis in Primary PCI for STEMI: A Systematic Review and Meta-Analysis. | 3.5 | 0 | Citations (PDF) |
| 628 | Efficacy and Safety of Zalunfiban by Creatinine Clearance Among Patients with ST-Elevation Myocardial Infarction: Analysis from the CELEBRATE Trial. | 1.5 | 0 | Citations (PDF) |
